Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
- Conditions
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT00445900
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
- Conditions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00438841
- Locations
- 🇺🇸
Oregon Health and Science University Cancer Institute, Portland, Oregon, United States
🇺🇸Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 68
- Registration Number
- NCT00432458
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 30
- Registration Number
- NCT00418132
- Locations
- 🇺🇸
New York University School of Medicine General Clinical Research Center, Bellevue Hospital, New York, New York, United States
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
- Conditions
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00412542
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Silvio Aime
- Target Recruit Count
- 24
- Registration Number
- NCT00406978
- Locations
- 🇮🇹
Div. Univ. Di Ematologia, Az. Osp. San Giovanni Battista, Torino, TO, Italy
🇮🇹Dip. Scienze Mediche & IRCAD-Università, UDA Ematologia, Novara, Italy
🇮🇹Servizio di Ematologia, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00400517
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2011-08-02
- Lead Sponsor
- Northport Veterans Affairs Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT00389935
- Locations
- 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Northport VAMC, Northport, New York, United States
Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT00390247
- Locations
- 🇭🇰
Renal Unit, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.